Workflow
血液透析浓缩液
icon
Search documents
山外山(688410):血液净化赛道国产龙头,设备回暖提供中短期催化、耗材与出海打开长期空间
Guotou Securities· 2025-08-18 15:39
2025 年 08 月 18 日 山外山(688410.SH) 血液净化赛道国产龙头,设备回暖提供 中短期催化、耗材与出海打开长期空间 血液透析行业持续增长为公司成长奠定坚实基础。 肾脏替代治疗患者数量持续增长,全球接受透析治疗的慢性肾衰竭患 者 2023 年达到 410 万人,10 年复合增长率约 5%。我国透析患者总量 2024 年达到 102 万人,近十年复合增速约 12%,新增透析患者数量、 透析患病率和发病率等指标在近年均呈现加速上升趋势。全球血液透 析服务+产品市场总规模(服务+产品)2023 年达到 810 亿欧元;我 国透析产品端市场规模预计 2025 年接近 300 亿元,年化复合增速约 6%,总体呈稳步上升趋势。 短期催化:设备招采终端需求回暖,公司业绩恢复快速增长。 公司设备类收入与终端招投标景气度呈现显著的正相关,若终端招投 标保持旺盛趋势,则对公司下一阶段业绩放量提供前瞻判断意义。 2023 年,由于公共卫生事件影响,血液透析设备需求呈现短期大幅 度提振,可以看到血透设备与 CRRT 设备招投标金额均在这一时期呈 现大幅攀升;与之相对的,2023 年,公司收入与利润后续均实现大幅 增 ...
三鑫医疗: 2025年半年度报告
Zheng Quan Zhi Xing· 2025-08-08 12:13
Core Viewpoint - Jiangxi Sanxin Medical Technology Co., Ltd. reported a revenue increase of 10.83% in the first half of 2025, driven by strong performance in blood purification products, which account for over 80% of total revenue [11][12]. Financial Performance - The company's operating income for the first half of 2025 was approximately 760.81 million yuan, compared to 686.45 million yuan in the same period last year, reflecting a growth of 10.83% [3]. - Net profit attributable to shareholders was approximately 115.12 million yuan, an increase of 8.35% from 106.25 million yuan year-on-year [3]. - The net cash flow from operating activities increased by 38.94% to approximately 189.19 million yuan [3]. Industry Overview - The global medical device market is projected to reach 623 billion USD in 2024, with a compound annual growth rate (CAGR) of approximately 8.1% from 2020 to 2024, and is expected to exceed 1 trillion USD by 2033 [4][5]. - The medical device industry is characterized as a knowledge-intensive and capital-intensive sector, with significant regulatory oversight due to its direct impact on human health [4]. - China's medical device market is the second largest globally, with a projected market size of approximately 595 billion yuan in 2024, growing at a rate of 2.9% year-on-year [4][5]. Company Positioning - The company is a key player in the medical device industry, focusing on research, manufacturing, and sales of blood purification products, drug delivery devices, and cardiothoracic surgery products [11]. - The company has established a comprehensive product chain for blood dialysis equipment and consumables, serving over 5,000 hospitals and dialysis centers domestically and internationally [11][12]. - The company has achieved significant advancements in domestic production of key materials for dialysis membranes, breaking the monopoly of foreign brands in this sector [12]. Market Trends - The medical device industry is experiencing a shift towards innovation, with policies encouraging the development of high-quality medical devices to enhance international competitiveness [7][8]. - The government has implemented measures to support the internationalization of medical device companies, including financial incentives and export credit insurance [5][6]. - The trend of centralized procurement is becoming normalized, with a focus on quality improvement and expansion of service coverage in the medical device sector [6][7].